1. Scrip
  3. >>South Korea

Korea’s First Homegrown CAR-T Therapy On Horizon

Curocell Files For Approval In LBCL

 
• By Jung Won Shin

Rimqarto is poised to become the first homegrown South Korean CAR-T therapy to gain domestic approval and looks set to provide new local competition to Kymriah.

CAR-T Therapy
Rimqarto Set To Compete With Kymriah In Korea (Shutterstock)

South Korean venture Curocell has filed for domestic regulatory approval of its next generation CD19-targeting drug Rimqarto (anbalcabtagene autoleucel or anbal-cel) for relapsed or refractory large B-cell lymphoma, taking a big step towards the possible launch of what would be the country’s first homegrown CAR-T therapy.

Rimqarto makes use of Curocell’s proprietary OVIS (OVercome Immune Suppression) technology that the venture says significantly reduces CAR-T cell “exhaustion” induced by the expression of PD-1 and TIGIT, two immune

More from South Korea

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Korea State R&D Fund Seeks Continuity To Enable Seamless Support

 
• By Jung Won Shin

The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.

More from Advanced Therapies